What is PHGUF stock price today?

PHGUF (Pharming Group N.V) stock is trading at $1.51 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PHGUF stock going up or down today?

PHGUF stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PHGUF stock now?

The decision to buy PHGUF depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PHGUF a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PHGUF based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PHGUF stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PHGUF is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PHGUF's P/E ratio?

P/E ratio data for PHGUF will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PHGUF's market cap?

PHGUF (Pharming Group N.V) has a market capitalization of $1.10 billion, making it a small-cap stock.

What is PHGUF's price to book ratio?

PHGUF trades at a price-to-book (P/B) ratio of 3.80, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PHGUF pay dividends?

PHGUF does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PHGUF's dividend yield?

PHGUF does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PHGUF stock a good long-term investment?

PHGUF's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PHGUF's revenue growth rate?

PHGUF has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, PHGUF is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in PHGUF?

Key risks for PHGUF include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PHGUF compare to its competitors?

Compare PHGUF to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PHGUF's performance and positioning.

What is PHGUF's stock price target for 2026?

Our AI model provides price targets for PHGUF based on fundamental analysis: Bull case $1.96 (+30%), Base case $1.74 (+15%), Bear case $1.36 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PHGUF?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PHGUF. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PHGUF's next earnings report?

PHGUF reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PHGUF - Pharming Group N.V

NYSE * Healthcare * Biotechnology

$1.51

+$0.00 (+0.00%)

About Pharming Group N.V

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

PHGUF Key Statistics

Market Cap

$1.10B

P/B Ratio

3.80

Revenue Growth

+0.1%

Profit Margin

0.0%

Employees

404

How PHGUF Compares to Peers

PHGUF has the fastest revenue growth among competitors

PHGUF is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PHGUF(This stock)	$1.10B	N/A	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Pharming Group N.V Company Information

Headquarters: Darwinweg 24, Leiden, Netherlands, 2333 CR, undefined
Website: www.pharming.com
Sector: Healthcare
Industry: Biotechnology

About Pharming Group N.V

PHGUF Key Statistics

How PHGUF Compares to Peers

Pharming Group N.V Company Information

Upcoming Events for PHGUF